- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in Johnson Johnson
J&J Discontinues Its Talc-based Baby Powder, Over Piling Cancer Lawsuits
According to the company, its baby powder produced from cornstarch is readily available in many countries. J&J has put the blame for the approximately 38,000 consumer lawsuits in North America on many misinformations and continuously refuted the allegations, pointing at many scientific studies with regulatory approvals which the company says demonstrate its products are safe to sell
Read MoreJ&J Files For Authorization Of COVID-19 Vaccine Booster
The filing comes after the FDA last week scheduled an Oct. 15 meeting of its expert advisory committee to discuss whether to authorize a second shot of J&J's single-dose vaccine.
Read MoreJohnson & Johnson Files Application To Conduct Study On Its COVID Vaccine In Adolescents
Union Health Minister Mansukh Mandaviya had said the approval would further boost the country's collective fight against the novel coronavirus infection.
Read MoreJohnson & Johnson Exploring Ways To Accelerate Delivery Of Its COVID Vaccine In India
The company also said as per a recent announcement by the Indian drug regulator, there is no longer a need to conduct bridging clinical trials of COVID-19 vaccines in India.
Read MoreSerum Institute Asks Govt To Take Up Inclusion Of Covishield In Vaccination Passport With EU
The letter also mentions that AstraZeneca-SII Covishield has been manufactured under technology transfer from Oxford/AstraZeneca and that clinical trials of the vaccine have been conducted successfully abroad and has been approved by MHRA for emergency use approval.
Read MoreIndia Seeks Funds From Quad Alliance To Match China's Vaccine Push: Source
Indian companies such as the Serum Institute of India (SII), Bharat Biotech, Biological E and Cadila Healthcare have the combined capacity to produce billions of doses of their own vaccines or contract-manufacture for others.
Read MoreWall Street Rallies On US Stimulus And Vaccine Hopes As Bond Markets Calm
Emerging market stocks rose 1.71%. MSCI's broadest index of Asia-Pacific shares outside Japan closed 1.83% higher, while Japan's Nikkei rose 2.41%.
Read MoreJ&J Waiting On New Plant Approval To Ship High Volumes Of Vaccine: Executive
J&J is also working to expand its manufacturing capacity globally and is in talks with potential new partners, Stoffels said, adding that he expects to be able to announce more manufacturing deals soon.
Read MoreFDA Advisory Panel To Review Johnson & Johnson COVID-19 Vaccine With Thumbs Up Expected
J&J's vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response.
Read MoreFrance's Sanofi To Help Johnson & Johnson Manufacture COVID-19 Vaccine
Sanofi will provide Johnson & Johnson access to the established infrastructure and expertise of its vaccine manufacturing plant in Marcy l'Etoile, France, to formulate and fill vials of Johnson & Johnson's Janssen COVID-19 vaccine candidate in 2021 at a rate of approximately 12 million doses per month.
Read MoreWall Street Closes Higher On Vaccine Lift; S&P 500, Nasdaq At Records
Johnson & Johnson rose 1.73% to help lift both the Dow and S&P 500 after the company said it could obtain late-stage trial results of a single-dose COVID-19 vaccine it is developing in January, earlier than expected.
Read MoreJ&J Starts Two-Dose Trial Of Its COVID-19 Candidate Vaccine In The UK
J&J signed an agreement for the two-dose global Phase III clinical trial with the British government in August, to run in parallel with a 60,000-person trial of a single shot of the experimental vaccine which was launched in September.
Read MoreMedicago's COVID-19 Vaccine Triggers Immune Response In Early-Stage Trial
Medicago is Canada's most advanced domestic COVID-19 vaccine project, but lags larger, global rivals such as Pfizer, AstraZeneca Plc and Johnson & Johnson which have begun late-stage trials.
Read MoreJohnson & Johnson Fails To Overturn $2.12 Billion Baby Powder Verdict, Plans Supreme Court Appeal
The Missouri Supreme Court let stand a June 23 decision by a state appeals court, which upheld a jury's July 2018 finding of liability but reduced J&J's payout from $4.69 billion after dismissing claims by some of the 22 plaintiffs.
Read MoreJ&J Plans To Test Its COVID-19 Vaccine In Ages 12-18 Soon
J&J started testing the vaccine in adults in a 60,000-volunteer Phase III study in late September. It had to pause the trial earlier this month because of a serious medical event in one participant. The study resumed last week.
Read More